Literature DB >> 10408869

Expression of interleukin 6 (IL-6) correlates with oestrogen receptor in human breast carcinoma.

G Fontanini1, D Campani, M Roncella, D Cecchetti, S Calvo, A Toniolo, F Basolo.   

Abstract

Multifunctional cytokines play important and only partially defined roles in mammary tumour development and progression. Normal human mammary epithelial cells constitutively produce interleukin 6 (IL-6), IL-8 and a non-secreted form of tumour necrosis factor. Transformation of mammary epithelial cells by different oncogenes is frequently associated with alterations of cytokine/growth factor production and responsiveness. In the present study we analysed the expression of IL-6 in 149 cases of invasive breast carcinoma and the data have been correlated with clinico-pathological variables including tumour size, histological grade, nodal status, and oestrogen and progesterone receptors, Ki67 and p53, protein expression. Though the majority of breast carcinomas expressed at least low levels of immunoreactive IL-6, we found that expression of this cytokine was inversely associated with histological tumour grade (P = 0.0017), but not with tumour size and nodal status. Ki67 positivity was inversely correlated with IL-6 expression (P = 0.027). Among biological parameters analysed, a direct association was found between the percentage of IL-6-positive cells and that of oestrogen (P = 0.00005) and progesterone (P = 0.025) receptor-positive cells. No correlation was observed between IL-6 and p53 protein expression. These data indicate that down-regulation of IL-6 is associated with highly malignant mammary carcinomas. It will be of interest to evaluate whether alterations of cytokines that are constitutively produced by mammary cells are also associated with high-grade tumours.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10408869      PMCID: PMC2362311          DOI: 10.1038/sj.bjc.6690394

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  29 in total

Review 1.  Cytokines as positive and negative regulators of tumor promotion and progression.

Authors:  D F Michiel; J J Oppenheim
Journal:  Semin Cancer Biol       Date:  1992-02       Impact factor: 15.707

2.  Regulation of mammary morphogenesis: evidence for extracellular matrix-mediated inhibition of ductal budding by transforming growth factor-beta 1.

Authors:  G B Silberstein; K C Flanders; A B Roberts; C W Daniel
Journal:  Dev Biol       Date:  1992-08       Impact factor: 3.582

3.  The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy.

Authors:  G Contesso; H Mouriesse; S Friedman; J Genin; D Sarrazin; J Rouesse
Journal:  J Clin Oncol       Date:  1987-09       Impact factor: 44.544

Review 4.  From adjuvant to neo-adjuvant chemotherapy in high-risk breast cancer: the experience of the Milan Cancer Institute. Steiner Award Lecture 1992.

Authors:  G Bonadonna
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

Review 5.  Transforming growth factor-beta.

Authors:  J Massagué; S Cheifetz; M Laiho; D A Ralph; F M Weis; A Zentella
Journal:  Cancer Surv       Date:  1992

6.  Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-beta 2.

Authors:  L Chen; Y Mory; A Zilberstein; M Revel
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

7.  Growth-stimulating activity of interleukin 6 on human mammary epithelial cells transfected with the int-2 gene.

Authors:  F Basolo; S Calvo; L Fiore; P G Conaldi; V Falcone; A Toniolo
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

8.  Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP beta (NF-IL6) activity by p53 species.

Authors:  L Margulies; P B Sehgal
Journal:  J Biol Chem       Date:  1993-07-15       Impact factor: 5.157

9.  Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro.

Authors:  D N Danforth; M K Sgagias
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

10.  Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression.

Authors:  C Lu; R S Kerbel
Journal:  J Cell Biol       Date:  1993-03       Impact factor: 10.539

View more
  16 in total

1.  Interleukin 6 G-174 C polymorphism and breast cancer risk.

Authors:  A M González-Zuloeta Ladd; A Arias Vásquez; J Witteman; A G Uitterlinden; J W Coebergh; A Hofman; B H Ch Stricker; C M van Duijn
Journal:  Eur J Epidemiol       Date:  2006-05-23       Impact factor: 8.082

2.  Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer.

Authors:  Tatsuo Shimura; Masahiko Shibata; Kenji Gonda; Yuko Murakami; Masaru Noda; Kazunoshin Tachibana; Noriko Abe; Tohru Ohtake
Journal:  Oncol Lett       Date:  2019-03-21       Impact factor: 2.967

3.  Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma.

Authors:  S Lhoták; L J Elavathil; S Vukmirović-Popović; W C Duivenvoorden; R G Tozer; G Singh
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  From mice to humans: identification of commonly deregulated genes in mammary cancer via comparative SAGE studies.

Authors:  Yuhui Hu; Hongxia Sun; Jeffrey Drake; Frances Kittrell; Martin C Abba; Li Deng; Sally Gaddis; Aysegul Sahin; Keith Baggerly; Daniel Medina; C Marcelo Aldaz
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

5.  Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.

Authors:  Paul J Mills; Sonia Ancoli-Israel; Barbara Parker; Loki Natarajan; Suzi Hong; Shamini Jain; Georgia R Sadler; Roland von Känel
Journal:  Brain Behav Immun       Date:  2007-08-15       Impact factor: 7.217

6.  IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells.

Authors:  Ariane Freund; Corine Chauveau; Jean-Paul Brouillet; Annick Lucas; Matthieu Lacroix; Anne Licznar; Françoise Vignon; Gwendal Lazennec
Journal:  Oncogene       Date:  2003-01-16       Impact factor: 9.867

7.  Estrogen receptor-alpha (ER-alpha) and defects in uterine receptivity in women.

Authors:  Bruce A Lessey; Wilder A Palomino; K B C Apparao; Steven L Young; Ruth A Lininger
Journal:  Reprod Biol Endocrinol       Date:  2006       Impact factor: 5.211

8.  Direct activation of oestrogen receptor-alpha by interleukin-6 in primary cultures of breast cancer epithelial cells.

Authors:  V Speirs; M J Kerin; D S Walton; C J Newton; S B Desai; S L Atkin
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

9.  The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype.

Authors:  B Iacopetta; F Grieu; D Joseph
Journal:  Br J Cancer       Date:  2004-01-26       Impact factor: 7.640

10.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients.

Authors:  T Bachelot; I Ray-Coquard; C Menetrier-Caux; M Rastkha; A Duc; J-Y Blay
Journal:  Br J Cancer       Date:  2003-06-02       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.